Form 8-K - Current report:
SEC Accession No. 0001493152-26-015170
Filing Date
2026-04-03
Accepted
2026-04-03 17:00:36
Documents
13
Period of Report
2026-04-02
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 45304
2 EX-99.1 ex99-1.htm EX-99.1 15257
3 GRAPHIC ex99-1_001.jpg GRAPHIC 5663
  Complete submission text file 0001493152-26-015170.txt   240324

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE mtnb-20260402.xsd EX-101.SCH 3038
5 XBRL LABEL FILE mtnb-20260402_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE mtnb-20260402_pre.xml EX-101.PRE 22374
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3204
Mailing Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921
Business Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921 908-484-8805
Matinas BioPharma Holdings, Inc. (Filer) CIK: 0001582554 (see all company filings)

EIN.: 463011414 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38022 | Film No.: 26838859
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)